Abiomed (NASDAQ:ABMD) will highlight the benefits of complete
revascularization with Protected PCI and the value of Impella
protocol-based treatment for survival and native heart recovery in
cardiogenic shock patients at the 31st Transcatheter Cardiovascular
Therapeutics (TCT) conference in San Francisco from September
25-29. During the conference, Abiomed will also offer hands-on
training to help physicians improve access and closure skills and
patient management expertise to achieve improved outcomes.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20190917005637/en/
Abiomed will showcase technological
innovations at TCT 2019, including Impella CP® with SmartAssist™,
which is designed to improve outcomes by using real-time
intelligence to optimize positioning, managing and weaning of the
Impella device for better patient care. (Graphic: Business
Wire)
Optimal Outcomes in Complex Patients Are Driven by Enabling
Complete Revascularization and Reducing Risk of Acute Kidney
Injury
During two breakfast symposia hosted by Abiomed,
interventionalists and fellows will present cases and best
practices using Impella devices to improve outcomes.
A symposium on Thursday, September 26, will feature best
practices for using percutaneous mechanical circulatory support to
enable complete revascularization in complex and sick patients.
The schedule for this symposium is below:
- Treating the Complex Patients: Impella Enabled Complete
Revascularization Thursday, September 26 6:30-7:45 a.m. PDT
Moscone South, Level 2, Room 209-210 Chair: William O’Neill,
MD
- Protected PCI: A Contemporary Look at Clinical Data from
cVAD Jeff Popma, MD
- The Value of Complete Revascularization in a Single
Setting Raj Patel, MD
- Driving Quality in PCI: The Benefits of Complete
Revascularization for Improvements in Ejection Fraction and Patient
Quality of Life Ehtisham Mahmud, MD
A second symposium on Friday, September 27, will highlight the
most interesting and complex cases submitted by fellows around the
globe. Attendees will learn techniques used for the procedures and
how to use hemodynamic support to achieve optimal outcomes.
The schedule for this symposium is below:
Management of Complex PCI Patients: Award Winning Case
Presentations
Friday, September 27 6:30-7:45 a.m. PDT Moscone South, Level 2,
Room 201-202 Co-Chairs: David Wohns, MD and George Dangas, MD
Panelists: Ayaz Rahman, MD; Justin Levisay, MD; Amir Kaki, MD
- Successful Resuscitation of Acute Cardiogenic Shock
Presenting as Ventricular Fibrillation via Bipella Approach
Yashwant Agrawal, MD
- Double Indication for Impella CP: High Risk Percutaneous
Coronary Intervention (PCI) and Acute Myocardial Infarction
Complicated by Cardiogenic Shock (AMICS) Rafael C. Ferreira,
MD
- IMPELLA Facilitated IVUS-Guided Left-Main with Double CTO
Revascularization in NSTEMI With Severe LV Impairment and Severe
Ischemic Mitral Regurgitation Kalaivani Mahadevan, MD
Improving Outcomes Through Hands-On Training for
Interventionalists
At the TCT training pavilion, Abiomed is hosting practical,
hands-on workshops on access and closure techniques, achieving
complete revascularization with Protected PCI, and implementing AMI
cardiogenic shock systems of care. Visit the TCT website to
register for training pavilion sessions.
The schedule for these training sessions is included below:
Thursday, September 26
- Access & Closure Faculty: Raj Tayal, MD; Amir Kaki,
MD; Adhir Shroff, MD; Jason Wollmuth, MD; Duane Pinto, MD; Paul
Mahoney, MD
- Protected PCI & Teach Faculty: Dan Burkhoff MD,
Jason Moreland, MD; Jon Robken, MD; Raj Patel, MD; Chadi Alraies,
MD; Hiram Bezerra, MD
- Shock Systems of Care: Best Practices from INOVA and
NCSI Faculty: Mir Babar Basir, DO; Alex Truesdell, MD; Sal
Mannino, MD; Michael Lim, MD
- Cardiogenic Shock & TEACH Faculty: Sanjog Kalra, MD;
Lynn Morris, MD
Saturday, September 28
- Treatment of Cardiogenic Shock Faculty: David A. Baran,
MD; Mir Babar Basir, DO; Arthur Garan, MD; Maximilian Halbe,
Director MCS; Colin Hirst, MD; Perwaiz M. Meraj, MD, FSCAI; L.
Christian Napp, MD
- Tips and Tricks for CHIP/Complex PCI Faculty: Dimitrios
Bliagos, MD; Ronald Caputo, MD; Jon C. George, MD; Annapoorna Kini,
MD; Kintur A. Sanghvi, MD, FACC, FSCAI; Goran Stankovic, MD, PhD;
Jason Wollmuth, MD
Physicians are also invited to visit booth #1727 to learn about
Impella CP with SmartAssist, experience Impella Connect, practice
their skills on a simulator, learn about new metrics and
algorithms, and have their questions answered by advanced Impella
trainers.
Impella CP with SmartAssist is the latest technological
development for the Impella platform and is designed to improve
patient outcomes with advanced algorithms and simplified patient
management. SmartAssist has been commercially available in the U.S.
since May, and launched in Europe in August.
Physicians to Share Updated NCSI Study Findings
At TCT 2019, physicians will present the latest results from the
National Cardiogenic Shock Initiative (NCSI) Study.
In all, Impella devices will be featured in more than 30
presentations at TCT 2019, focusing on topics such as:
- STEMI, Cardiac Arrest, and Cardiogenic Shock: Part 1
Featured presentation: LV Unloading to Reduce Infarct Size:
Rationale, Completed Studies, and Ongoing Trials Navin Kapur, MD
Thursday, September 26 4:45 p.m. PDT Moscone Center Room
151/153
- STEMI, Cardiac Arrest, and Cardiogenic Shock: Part 2
Featured presentation: While Awaiting More Clinical Trial Data:
Real-World Approaches to Cardiogenic Shock and Hemodynamic Support
Alex Truesdell, MD Friday, September 27 4:20 p.m. PDT Moscone
Center Room 151/153
- High Impact Clinical Research: Management of Cardiogenic
Shock Featured presentation: Impact of Right Ventricular
Dysfunction in Acute Myocardial Infarction Complicated by
Cardiogenic Shock Mir Babar Basir, DO Saturday, September 28 10:15
a.m. PDT Moscone Center Innovation and Keynote Theater
Investor Meeting
Investors are invited to join Abiomed’s annual investor meeting
on Thursday, September 26. Jeff Popma, MD, will present on:
Treating the Complex Patients: Impella Enabled Complete
Revascularization. To request attendance, please email
ir@abiomed.com.
ABOUT IMPELLA HEART PUMPS
The Impella 2.5® and Impella CP® devices are U.S. FDA PMA
approved to treat certain advanced heart failure patients
undergoing elective and urgent percutaneous coronary interventions
(PCI) such as stenting or balloon angioplasty, to re-open blocked
coronary arteries. The Impella 2.5, Impella CP, Impella CP with
SmartAssist™, Impella 5.0® and Impella LD® are U.S. FDA approved
heart pumps used to treat heart attack or cardiomyopathy patients
in cardiogenic shock, and have the unique ability to enable native
heart recovery, allowing patients to return home with their own
heart. The Impella RP® is U.S. FDA approved to treat right heart
failure or decompensation following left ventricular assist device
implantation, myocardial infarction, heart transplant, or
open-heart surgery.
In Europe, the Impella 2.5, Impella CP and Impella CP with
SmartAssist are CE marked for treatment of high-risk PCI and AMI
cardiogenic shock patients for up to 5 days. Impella 5.0 and
Impella LD are CE marked to treat heart attack or cardiomyopathy
patients in cardiogenic shock for up to 10 days. The Impella 5.5™
heart pump is CE marked to treat heart attack or cardiomyopathy
patients in cardiogenic shock for up to 30 days. The Impella RP is
CE marked to treat right heart failure or decompensation following
left ventricular assist device implantation, myocardial infarction,
heart transplant, open-heart surgery, or refractory ventricular
arrhythmia.
To learn more about the Impella platform of heart pumps,
including their approved indications and important safety and risk
information associated with the use of the devices, please visit:
www.impella.com.
ABOUT ABIOMED
Based in Danvers, Massachusetts, USA, Abiomed, Inc. is a leading
provider of medical devices that provide circulatory support. Our
products are designed to enable the heart to rest by improving
blood flow and/or performing the pumping of the heart. For
additional information, please visit: www.abiomed.com.
Abiomed, Impella, Impella 2.5, Impella 5.0, Impella LD, Impella
CP, Impella RP, and Impella Connect are registered trademarks of
Abiomed, Inc., and are registered in the U.S. and certain foreign
countries. Impella BTR, Impella 5.5, Impella ECP, CVAD Study, and
SmartAssist are pending trademarks of Abiomed, Inc.
FORWARD-LOOKING STATEMENTS
This release contains forward-looking statements, including
statements regarding development of Abiomed's existing and new
products, the company's progress toward commercial growth, and
future opportunities and expected regulatory approvals. The
company's actual results may differ materially from those
anticipated in these forward-looking statements based upon a number
of factors, including uncertainties associated with development,
testing and related regulatory approvals, including the potential
for future losses, complex manufacturing, high quality
requirements, dependence on limited sources of supply, competition,
technological change, government regulation, litigation matters,
future capital needs and uncertainty of additional financing, and
other risks and challenges detailed in the company's filings with
the Securities and Exchange Commission, including the most recently
filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
Readers are cautioned not to place undue reliance on any
forward-looking statements, which speak only as of the date of this
release. The company undertakes no obligation to publicly release
the results of any revisions to these forward-looking statements
that may be made to reflect events or circumstances that occur
after the date of this release or to reflect the occurrence of
unanticipated events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190917005637/en/
Tom Langford Director, Communications and Public Relations
978-882-8408 tlangford@abiomed.com
Ingrid Goldberg Ward Director, Investor Relations 978-646-1590
igoldberg@abiomed.com
ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From Sep 2023 to Sep 2024